Click For Versea Ophthalmics Homepage

Verséa Ophthalmics, headed by Rob Sambursky, MD, President, is on a mission to revolutionize eye care by delivering innovative solutions for the diagnosis, treatment, and management of ocular surface diseases.

A newly launched product portfolio consists of a novel, Tear-based, Point-of-Care (T-POC) quantitative testing platform and complementary allograft therapeutics that will enhance clinical management and inform treatment decisions that ultimately lead to better patient care.